Pure Global
NCT06206590

Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates Born to ≤32-week Preterm Infants or Infected Mothers During Pregnancy
Guangdong Women and Children Hospital·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neonatal Disease
Drug/Device/Intervention
Whole-proteomic assay
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Guangdong Women and Children Hospital
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Dec 31, 2025
Enrollment
116 participants
Primary outcome

The incidence and mortality of shock

Summary

1. Explore 32 weeks of premature infants or maternal pregnancy infection of newborn septic
 shock maternal influence factors. 2. Through maternal blood samples before delivery and labor
 cord blood sample screening and septic shock related proteomics analysis, explore the
 relationship between the difference protein and septic shock and prognosis, and explore the
 pathway mechanism, in order to prevent and reduce the occurrence of septic shock in premature
 infants

ICD-10 classifications
Neonatal aspiration syndrome, unspecifiedNeonatal comaNeonatal aspiration syndromesRespiratory condition of newborn, unspecifiedNeonatal diabetes mellitus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06206590
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06206590 through Pure Global AI's free database. This phase not specified trial is sponsored by Guangdong Women and Children Hospital and is currently Recruiting. The study focuses on Neonatal Disease. Target enrollment is 116 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.